Da kommt demnächst etwas, siehe Volumen
chart.bigcharts.com/bc3/quickchart/...345&mocktick=1&rand=665" style="max-width:560px" >
Top-News
LGND -Ligand Pharmaceuticals
Beiträge:
27
Zugriffe: 11.939 / Heute: 1
Zugriffe: 11.939 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +66,39%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +61,91%
Xtrackers MSCI USA Communication Services UCITS ETF 1D
Perf. 12M: +53,61%
Xtrackers MSCI World Communication Services UCITS ETF 1C
Perf. 12M: +50,55%
der letzte war gut mit sehr gutem Gewinn und deutlich höheren Umsätzen am 31.Oktober,der nächste soll angeblich erst am 24.2. kommen,dann könnte sie wohl auf 19 steigen,Ontak scheint Potential als Krebsmittel zu haben 50% Erfolg bei Lymphozyten-Leukämie
Sollten die 12,60 noch erreicht werden,
lege ich mir vielleicht welche ins Depot.
hey ya, Buju
lege ich mir vielleicht welche ins Depot.
hey ya, Buju
Hat Jemand aktuellere News ?
Habe nur etwas Finanzen.Net vom 10.02.04 gefunden:
Alle Aktien in dieser Analyse: Ligand Pharmaceuticals Inc.
Kurzzusammenfassung:
Analyst: Friedman, Billings Ramsey & Co
Rating: Outperform Kurs: n/A
KGV: Kursziel: 20 USD
Update: upgrade WKN: 895777
Update Ligand Pharmaceuticals Inc.: Outperform
10.02.2004 16:36:01
Die Analysten von Friedman, Billings Ramsey & Co. stufen in ihrer Analyse vom 9. Februar die Aktie des US-amerikanischen Pharmaunternehmens Ligand Pharmaceuticals Inc. von bisher "Market Perform" auf nun "Outperform" herauf. Das Kursziel erhöhen die Analysten von 14 Dollar auf nun 20 Dollar.
-mos-
**************************************************
Bei so einem Anstieg hoffe ich mal, das noch mehr kommt bzw. die Tage ein paar schöne NEws auftauchen...
Grüsse
Toke
Habe nur etwas Finanzen.Net vom 10.02.04 gefunden:
Alle Aktien in dieser Analyse: Ligand Pharmaceuticals Inc.
Kurzzusammenfassung:
Analyst: Friedman, Billings Ramsey & Co
Rating: Outperform Kurs: n/A
KGV: Kursziel: 20 USD
Update: upgrade WKN: 895777
Update Ligand Pharmaceuticals Inc.: Outperform
10.02.2004 16:36:01
Die Analysten von Friedman, Billings Ramsey & Co. stufen in ihrer Analyse vom 9. Februar die Aktie des US-amerikanischen Pharmaunternehmens Ligand Pharmaceuticals Inc. von bisher "Market Perform" auf nun "Outperform" herauf. Das Kursziel erhöhen die Analysten von 14 Dollar auf nun 20 Dollar.
-mos-
**************************************************
Bei so einem Anstieg hoffe ich mal, das noch mehr kommt bzw. die Tage ein paar schöne NEws auftauchen...
Grüsse
Toke
Hat da wirklich keiner News ?
Muß ich mal auf die Suche gehen wenn ich morgen zeit habe...
Muß ich mal auf die Suche gehen wenn ich morgen zeit habe...
auf die ich gewartet habe ;-))) Quelle: Finanzen.net
Ligand erzielt Gewinn im vierten Quartal, Aktie +18 Prozent
03.03.2004 14:12:00
Der amerikanische Pharmakonzern Ligand Pharmaceuticals Inc. konnte im vierten Quartal in die Gewinnzone zurückkehren.
Das Unternehmen, welches auf die Entwicklung von Krebsmedikamenten spezialisiert ist, erwirtschaftete im Berichtszeitraum einen Nettogewinn von 5,9 Mio. Dollar bzw. 8 Cents je Aktie, nachdem im Vorjahresquartal ein Nettoverlust von 6,7 Mio. Dollar bzw. ein Verlust von 9 Cents je Aktie angefallen war. Der Konzernumsatz konnte gegenüber dem Vorjahresquartal (27,32 Mio. Dollar) auf 57,61 Mio. Dollar gesteigert werden. Analysten hatten im Vorfeld einen Nettogewinn von durchschnittlich 3 Cents je Aktie sowie einen Konzernumsatz von 53,82 Mio. Dollar prognostiziert.
Im abgelaufenen Geschäftsjahr verbuchte Ligand einen Nettoverlust von 37,46 Mio. Dollar bzw. 53 Cents je Aktie, nachdem im Vorjahr ein Verlust von 32,60 Mio. Dollar bzw. ein Verlust von 47 Cents je Aktie angefallen war. Der Konzernumsatz lag mit 141,14 Mio. Dollar über dem Niveau des Vorjahres (96,64 Mio. Dollar).
Die Aktie von Ligand gewinnt vorbörslich an der NASDAQ 16,50 Prozent auf 18,82 Dollar.
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Kein Wunder, dass die so hohschnellt....
Was denkt Ihr ? Wie weit die mittelfristig geht ?
Grüsse
Toke
Ligand erzielt Gewinn im vierten Quartal, Aktie +18 Prozent
03.03.2004 14:12:00
Der amerikanische Pharmakonzern Ligand Pharmaceuticals Inc. konnte im vierten Quartal in die Gewinnzone zurückkehren.
Das Unternehmen, welches auf die Entwicklung von Krebsmedikamenten spezialisiert ist, erwirtschaftete im Berichtszeitraum einen Nettogewinn von 5,9 Mio. Dollar bzw. 8 Cents je Aktie, nachdem im Vorjahresquartal ein Nettoverlust von 6,7 Mio. Dollar bzw. ein Verlust von 9 Cents je Aktie angefallen war. Der Konzernumsatz konnte gegenüber dem Vorjahresquartal (27,32 Mio. Dollar) auf 57,61 Mio. Dollar gesteigert werden. Analysten hatten im Vorfeld einen Nettogewinn von durchschnittlich 3 Cents je Aktie sowie einen Konzernumsatz von 53,82 Mio. Dollar prognostiziert.
Im abgelaufenen Geschäftsjahr verbuchte Ligand einen Nettoverlust von 37,46 Mio. Dollar bzw. 53 Cents je Aktie, nachdem im Vorjahr ein Verlust von 32,60 Mio. Dollar bzw. ein Verlust von 47 Cents je Aktie angefallen war. Der Konzernumsatz lag mit 141,14 Mio. Dollar über dem Niveau des Vorjahres (96,64 Mio. Dollar).
Die Aktie von Ligand gewinnt vorbörslich an der NASDAQ 16,50 Prozent auf 18,82 Dollar.
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Kein Wunder, dass die so hohschnellt....
Was denkt Ihr ? Wie weit die mittelfristig geht ?
Grüsse
Toke
mir mal bitte einer sagen warum der kurs auf 5,50 fällt,
hat jemand Information betr. Ligand ?
hat jemand Information betr. Ligand ?
Biosante, Dendreon, Genelabs, Genta, PHARMACOPEIA, Merck, Tenet (jetzt fällt mir kein Unternehmen mehr ein - andererseits ist ja eigentlich eine ganz bemerkenswerte Liste) heute Ligand im freinen Fall nach unten.
Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for Front-Line Non-Small Cell Lung Cancer
Monday March 28, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--March 28, 2005--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - News) announced today that its two pivotal Phase III studies of Targretin® (bexarotene) capsules in front-line combination therapy with standard chemotherapy to treat advanced non-small cell lung cancer (NSCLC) did not meet their endpoints of improved overall survival and projected two-year survival. The studies were designed to evaluate whether adding Targretin to front-line cisplatin/vinorelbine or carboplatin/paclitaxel chemotherapy extends the survival of patients with advanced (Stage IIIB with pleural effusion or Stage IV) NSCLC.
In SPIRIT I, patients were randomized to two arms, receiving either cisplatin/vinorelbine chemotherapy alone or in combination with Targretin capsules. SPIRIT II enrolled patients to two arms receiving either carboplatin/paclitaxel alone or in combination with Targretin capsules.
For both studies, the primary endpoint was overall survival and the secondary endpoint was Kaplan-Meier projected two-year survival. No statistically significant differences in primary or secondary endpoints in the intent to treat population were seen in either trial. An initial trend analysis of sizeable sub-groups in the treatment arms of both trials suggests a relationship between Targretin dose intensity and biomarker response (i.e., triglyceride elevations) with survival, and is the subject of further evaluations in parallel with other risk factor analysis to better identify the determinants of benefit or risk to Targretin in a first-line setting.
Both studies recruited patients from both U.S. and international sites, with SPIRIT I having the largest proportion of patients from outside of North America and SPIRIT II having the largest proportion of patients from the U.S. A well-balanced demographic distribution across the two arms was achieved in both trials, consistent with what has been reported in other similar, large-scale phase III trials conducted recently in a similar patient population.
The initial daily dose of Targretin in both trials was similar to that used in prior phase II studies in which a positive trend in survival had been observed. Doses of carboplatin and vinorelbine in SPIRIT I and carboplatin and paclitaxel in SPIRIT II were also consistent with standard chemotherapy regimens used in most recent large-scale trials.
Targretin is a selective retinoid X receptor (RXR) modulator with proven efficacy as monotherapy in the treatment of cutaneous T-cell lymphoma (CTCL). RXR levels in the tumor have been shown to be an independent predictor of survival in NSCLC and in other solid tumors.
"We are very disappointed in the lack of survival advantage of Targretin/dual chemotherapy triple therapy in first-line NSCLC patients, particularly in view of the consistent positive trends seen in several phase I/II studies and in the preclinical data that provided strong mechanistic support for a potentially beneficial Targretin/chemotherapy combination," said Andres Negro-Vilar, M.D. Ph.D., Ligand's executive vice president for research and development and chief scientific officer. "We know that several other targeted therapies combined with chemotherapy have also fallen short of a survival advantage in a first-line setting while in some cases proving efficacious in second- and third-line treatment. We believe SPIRIT I and II provided robust data to evaluate the value of adding Targretin to combo chemotherapy in the front-line setting and based upon those results now plan to continue to evaluate the potential of Targretin to provide benefit for second- and third-line patients."
In the SPIRIT trials, the addition of Targretin to both chemotherapy regimens was generally well tolerated. Adverse events were similar to those previously reported in studies with chemotherapy treatment and with Targretin. Regarding serious adverse events with an incidence greater than 1%, there was an increase in the incidence of neutropenia in SPIRIT I in the Targretin arm principally attributed by the investigators to combo chemotherapy. An increase in febrile neutropenia was seen in the chemotherapy control arm of that study. No significant differences in the incidence of serious adverse events between the arms were seen in SPIRIT II. Adverse events -- grade 3 and 4 -- that occurred more frequently with Targretin included hypertriglyceridemia in both trials, neutropenia, asthenia and dehydration in SPIRIT II and dyspnea in SPIRIT I. These differences were recorded for all AEs that reached a level of 5% frequency in any arm.
Ligand will continue to analyze the data and plans to make a detailed scientific presentation at the upcoming ASCO or other near-term scientific conferences.
"While this is disappointing news for all stakeholders, we expect to continue to analyze the data from SPIRIT I and II and apply it to the continued development of Targretin in NSCLC," said David E. Robinson, Ligand's chairman, president and CEO. "As a company, we will also remain focused on the near-term priority of accelerating the commercial development of Avinza® and ONTAK® as principal drivers of the company's growth as we await the approval of near-term corporate partner products."
Da fragt man sich doch ob ein Einzelinvestment in dieser Branche Sinn macht oder nicht?
xpfuture
Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for Front-Line Non-Small Cell Lung Cancer
Monday March 28, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--March 28, 2005--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - News) announced today that its two pivotal Phase III studies of Targretin® (bexarotene) capsules in front-line combination therapy with standard chemotherapy to treat advanced non-small cell lung cancer (NSCLC) did not meet their endpoints of improved overall survival and projected two-year survival. The studies were designed to evaluate whether adding Targretin to front-line cisplatin/vinorelbine or carboplatin/paclitaxel chemotherapy extends the survival of patients with advanced (Stage IIIB with pleural effusion or Stage IV) NSCLC.
In SPIRIT I, patients were randomized to two arms, receiving either cisplatin/vinorelbine chemotherapy alone or in combination with Targretin capsules. SPIRIT II enrolled patients to two arms receiving either carboplatin/paclitaxel alone or in combination with Targretin capsules.
For both studies, the primary endpoint was overall survival and the secondary endpoint was Kaplan-Meier projected two-year survival. No statistically significant differences in primary or secondary endpoints in the intent to treat population were seen in either trial. An initial trend analysis of sizeable sub-groups in the treatment arms of both trials suggests a relationship between Targretin dose intensity and biomarker response (i.e., triglyceride elevations) with survival, and is the subject of further evaluations in parallel with other risk factor analysis to better identify the determinants of benefit or risk to Targretin in a first-line setting.
Both studies recruited patients from both U.S. and international sites, with SPIRIT I having the largest proportion of patients from outside of North America and SPIRIT II having the largest proportion of patients from the U.S. A well-balanced demographic distribution across the two arms was achieved in both trials, consistent with what has been reported in other similar, large-scale phase III trials conducted recently in a similar patient population.
The initial daily dose of Targretin in both trials was similar to that used in prior phase II studies in which a positive trend in survival had been observed. Doses of carboplatin and vinorelbine in SPIRIT I and carboplatin and paclitaxel in SPIRIT II were also consistent with standard chemotherapy regimens used in most recent large-scale trials.
Targretin is a selective retinoid X receptor (RXR) modulator with proven efficacy as monotherapy in the treatment of cutaneous T-cell lymphoma (CTCL). RXR levels in the tumor have been shown to be an independent predictor of survival in NSCLC and in other solid tumors.
"We are very disappointed in the lack of survival advantage of Targretin/dual chemotherapy triple therapy in first-line NSCLC patients, particularly in view of the consistent positive trends seen in several phase I/II studies and in the preclinical data that provided strong mechanistic support for a potentially beneficial Targretin/chemotherapy combination," said Andres Negro-Vilar, M.D. Ph.D., Ligand's executive vice president for research and development and chief scientific officer. "We know that several other targeted therapies combined with chemotherapy have also fallen short of a survival advantage in a first-line setting while in some cases proving efficacious in second- and third-line treatment. We believe SPIRIT I and II provided robust data to evaluate the value of adding Targretin to combo chemotherapy in the front-line setting and based upon those results now plan to continue to evaluate the potential of Targretin to provide benefit for second- and third-line patients."
In the SPIRIT trials, the addition of Targretin to both chemotherapy regimens was generally well tolerated. Adverse events were similar to those previously reported in studies with chemotherapy treatment and with Targretin. Regarding serious adverse events with an incidence greater than 1%, there was an increase in the incidence of neutropenia in SPIRIT I in the Targretin arm principally attributed by the investigators to combo chemotherapy. An increase in febrile neutropenia was seen in the chemotherapy control arm of that study. No significant differences in the incidence of serious adverse events between the arms were seen in SPIRIT II. Adverse events -- grade 3 and 4 -- that occurred more frequently with Targretin included hypertriglyceridemia in both trials, neutropenia, asthenia and dehydration in SPIRIT II and dyspnea in SPIRIT I. These differences were recorded for all AEs that reached a level of 5% frequency in any arm.
Ligand will continue to analyze the data and plans to make a detailed scientific presentation at the upcoming ASCO or other near-term scientific conferences.
"While this is disappointing news for all stakeholders, we expect to continue to analyze the data from SPIRIT I and II and apply it to the continued development of Targretin in NSCLC," said David E. Robinson, Ligand's chairman, president and CEO. "As a company, we will also remain focused on the near-term priority of accelerating the commercial development of Avinza® and ONTAK® as principal drivers of the company's growth as we await the approval of near-term corporate partner products."
Da fragt man sich doch ob ein Einzelinvestment in dieser Branche Sinn macht oder nicht?
xpfuture
Ums mal kurz zu formulieren: Das sich in der Phase III befindende Lungenkremsmedikament Targretin erbrachte nicht die gewünschten Ergebnisse.
xpfuture
xpfuture
zum ersten mal, mal wieder hohe Umsätze..meine Einschätzung Ligand steigt
einige in der nächsten Zeit anstehenden Entscheidungen der FDA
(Verkleinert auf 93%) 
warum bei dieser Pipeline und den Partnern der Kurs so im Keller ist?
www.pharmacopeia.com/media/PIPELINE_February_2010.pdf
www.pharmacopeia.com/media/PIPELINE_February_2010.pdf
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligand’s novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Association’s 74th Scientific Sessions meeting underway in San Francisco.
Highlights of the single-ascending dose trial involving a total of 56 subjects include:
LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events.
LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing.
After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes.
Fasting plasma glucose was reduced by 57 mg/dL (placebo-adjusted) in subjects with type 2 diabetes, suggesting a robust response in this acute study.
“Management of type 2 diabetes is one of the largest and fastest-growing global medical markets, and despite many approved therapies there is enormous need for new mechanisms to treat the disease. We believe that glucagon receptor antagonism is one of the most promising areas of novel research,” commented Matthew W. Foehr, Executive Vice President and Chief Operating Officer of Ligand. “We are highly encouraged by the results of this Phase 1 trial, which give us confidence in the continued development of this promising novel therapeutic with once-daily dosing and best-in-class properties. We consider the LGD-6972 program to be one of the most exciting in our portfolio of unpartnered assets.”
About Ligand’s Glucagon Receptor Antagonist Program
Glucagon is a hormone produced by the pancreas that stimulates the liver to produce glucose (sugar). Overproduction of glucose by the liver is an important cause of high glucose levels in patients with type 2 diabetes and is believed to be due in part to inappropriately elevated levels of glucagon. High glucose levels can cause diabetic complications such as blindness and kidney disease. Glucagon receptor antagonists are designed to lower glucose levels by reducing the production of glucose by the liver. Glucagon receptor antagonists are novel molecules that have demonstrated a reduction of glucose and hemoglobin A1c in mid-stage clinical trials.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying our portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
Forward-Looking Statements
This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. These include statements regarding data analysis and evaluation of LGD-6972 and/or other Glucagon receptor antagonists, utility or potential benefits to patients, plans for continued development and further studies of such compounds. Actual events or results may differ from our expectations. For example, there can be no assurance that other trials or evaluations of LGD-6972 and/or other Glucagon receptor antagonists will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that such compounds will provide utility or benefits to certain patients, that any presentations will be favorably received, that such compounds will be useful with other drugs, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of these drugs will be initiated, completed or successful or that our rights to LGD-6972 and/or other Glucagon receptor antagonists will not be successfully challenged. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Highlights of the single-ascending dose trial involving a total of 56 subjects include:
LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events.
LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing.
After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes.
Fasting plasma glucose was reduced by 57 mg/dL (placebo-adjusted) in subjects with type 2 diabetes, suggesting a robust response in this acute study.
“Management of type 2 diabetes is one of the largest and fastest-growing global medical markets, and despite many approved therapies there is enormous need for new mechanisms to treat the disease. We believe that glucagon receptor antagonism is one of the most promising areas of novel research,” commented Matthew W. Foehr, Executive Vice President and Chief Operating Officer of Ligand. “We are highly encouraged by the results of this Phase 1 trial, which give us confidence in the continued development of this promising novel therapeutic with once-daily dosing and best-in-class properties. We consider the LGD-6972 program to be one of the most exciting in our portfolio of unpartnered assets.”
About Ligand’s Glucagon Receptor Antagonist Program
Glucagon is a hormone produced by the pancreas that stimulates the liver to produce glucose (sugar). Overproduction of glucose by the liver is an important cause of high glucose levels in patients with type 2 diabetes and is believed to be due in part to inappropriately elevated levels of glucagon. High glucose levels can cause diabetic complications such as blindness and kidney disease. Glucagon receptor antagonists are designed to lower glucose levels by reducing the production of glucose by the liver. Glucagon receptor antagonists are novel molecules that have demonstrated a reduction of glucose and hemoglobin A1c in mid-stage clinical trials.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying our portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
Forward-Looking Statements
This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. These include statements regarding data analysis and evaluation of LGD-6972 and/or other Glucagon receptor antagonists, utility or potential benefits to patients, plans for continued development and further studies of such compounds. Actual events or results may differ from our expectations. For example, there can be no assurance that other trials or evaluations of LGD-6972 and/or other Glucagon receptor antagonists will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that such compounds will provide utility or benefits to certain patients, that any presentations will be favorably received, that such compounds will be useful with other drugs, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of these drugs will be initiated, completed or successful or that our rights to LGD-6972 and/or other Glucagon receptor antagonists will not be successfully challenged. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other risk factors affecting Ligand's business can be found in prior press releases available via www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
www.businesswire.com/news/home/...g-Authorization#.VJRUdP8FBLI
hat das Kursziel für Ligand Pharmaceuticals Inc von 74 auf 94 USD angehoben, aber die Einstufung auf "Buy" belassen.
Kurs bricht ein.
Da dürfte noch einiges drin sein.
citronresearch.com/wp-content/uploads/...-Pharmaceuticals.pdf
Da dürfte noch einiges drin sein.
citronresearch.com/wp-content/uploads/...-Pharmaceuticals.pdf
Short-Attacke
www.fool.com/investing/2019/01/16/...s-plummeted-16-toda.aspx
Ligand meldet Zahlen für 2018
- 2018 Umsatz ~251 Mio. $ (vgl. 141 Mio. $ in 2017)
- 2018 Gewinn ~143 Mio. $ (vgl. 13 Mio. $ in 2017)
investor.ligand.com/press-releases/detail/...r-2018-financial
Ligand meldet Zahlen für Q1/19
- Umsatz 43 Mio. $
- Gewinn aus dem Verkauf der Promacta Lizenz 813 Mio. $
- Gewinn 666 Mio. $
investor.ligand.com/press-releases/detail/...inancial-results
nachkaufen? Ich bin investiert....ich glaube, ich werde nochmals nachlegen.
Ligand meldet Zahlen für Q2/19
- Umsatz 25 Mio. $
- Verlust 14 Mio. $
- Cash 1,33 Mrd. $
- MK 1,88 Mrd. $
investor.ligand.com/press-releases/detail/...inancial-results
www.analystratings.com/articles/...nd-and-seagen-nasdaq-sgen/
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Ligand Pharmaceuticals Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 26 | LGND -Ligand Pharmaceuticals | buju | Balu4u | 30.07.21 14:57 |
